Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth

Zhenzhen Liu, Jin Qing Liu, Yun Shi, Xiaotong Zhu, Zhihao Liu, Ming Song Li, Jianhua Yu, Lai Chu Wu, Yukai He, Guoqiang Zhang, Xue Feng Bai

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Epstein-Barr virus-induced gene 3 (EBI3) encoded protein can form heterodimers with IL-27P28, and IL-12P35 to form IL-27, and IL-35. However, IL-27 stimulates, whereas IL-35 inhibits antitumor T-cell responses. IL-27 also limits the Foxp3 + regulatory T cell (Treg) population, whereas IL-35 has been shown to expand Tregs and foster Treg suppressive functions. It remains unclear which group of forces are dominant during antitumor T-cell responses. In this study, we evaluated the tumor growth and antitumor T-cell responses in EBI3-deficient mice that lack both IL-27 and IL-35. We found that injecting B16 melanoma cells into EBI3-deficient C57BL/6 mice, or J558 plasmacytoma cells into EBI3-deficient BALB/c mice resulted in significantly increased tumor growth relative to those implanted in wild-type control mice. Tumors from EBI3-deficient mice contained significantly decreased proportions of CD8 + T cells and increased proportions of CD4 + FoxP3 + Treg cells as compared to those from EBI3-intact mice. Tumor-infiltrating T cells from EBI3-deficient mice were impaired in their capacity to produce IFNγ. Phenotypically, Tregs from EBI3-deficient mice were highly suppressive and produced IL-10 in the tumor microenvironment. Depletion of Tregs or inactivation of the IL-10 pathway significantly abrogated tumor growth enhancement in Ebi3 −/− mice. Finally, we showed that Ebi3 −/− mice administered a melanoma vaccine failed to mount a CD8 + T-cell response and the vaccine failed to confer tumor rejection in EBI3-deficient mice. Taken together, these results suggest that Ebi3 −/− mice show a phenotype of IL-27-deficiency rather than IL-35-deficiency during anti-tumor T-cell responses. Thus, our results suggest that endogenous IL-27 is critical for both spontaneous and vaccine-induced antitumor T-cell responses.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalOncoImmunology
Volume4
Issue number7
DOIs
StatePublished - Jan 1 2015

Fingerprint

Human Herpesvirus 4
Interleukin-27
T-Lymphocytes
Growth
Genes
Neoplasms
Vaccines
Regulatory T-Lymphocytes
Interleukin-10
Interleukin-12 Subunit p35
Experimental Melanomas
Plasmacytoma
Tumor Microenvironment
Inbred C57BL Mouse
Melanoma
Phenotype

Keywords

  • Epstein-Barr virus-induced gene 3
  • IL-27
  • IL-35
  • Treg
  • Tumor immunity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth. / Liu, Zhenzhen; Liu, Jin Qing; Shi, Yun; Zhu, Xiaotong; Liu, Zhihao; Li, Ming Song; Yu, Jianhua; Wu, Lai Chu; He, Yukai; Zhang, Guoqiang; Bai, Xue Feng.

In: OncoImmunology, Vol. 4, No. 7, 01.01.2015, p. 1-10.

Research output: Contribution to journalArticle

Liu, Zhenzhen ; Liu, Jin Qing ; Shi, Yun ; Zhu, Xiaotong ; Liu, Zhihao ; Li, Ming Song ; Yu, Jianhua ; Wu, Lai Chu ; He, Yukai ; Zhang, Guoqiang ; Bai, Xue Feng. / Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth. In: OncoImmunology. 2015 ; Vol. 4, No. 7. pp. 1-10.
@article{be0e9ffb35df4fe6976902bf048ace0b,
title = "Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth",
abstract = "Epstein-Barr virus-induced gene 3 (EBI3) encoded protein can form heterodimers with IL-27P28, and IL-12P35 to form IL-27, and IL-35. However, IL-27 stimulates, whereas IL-35 inhibits antitumor T-cell responses. IL-27 also limits the Foxp3 + regulatory T cell (Treg) population, whereas IL-35 has been shown to expand Tregs and foster Treg suppressive functions. It remains unclear which group of forces are dominant during antitumor T-cell responses. In this study, we evaluated the tumor growth and antitumor T-cell responses in EBI3-deficient mice that lack both IL-27 and IL-35. We found that injecting B16 melanoma cells into EBI3-deficient C57BL/6 mice, or J558 plasmacytoma cells into EBI3-deficient BALB/c mice resulted in significantly increased tumor growth relative to those implanted in wild-type control mice. Tumors from EBI3-deficient mice contained significantly decreased proportions of CD8 + T cells and increased proportions of CD4 + FoxP3 + Treg cells as compared to those from EBI3-intact mice. Tumor-infiltrating T cells from EBI3-deficient mice were impaired in their capacity to produce IFNγ. Phenotypically, Tregs from EBI3-deficient mice were highly suppressive and produced IL-10 in the tumor microenvironment. Depletion of Tregs or inactivation of the IL-10 pathway significantly abrogated tumor growth enhancement in Ebi3 −/− mice. Finally, we showed that Ebi3 −/− mice administered a melanoma vaccine failed to mount a CD8 + T-cell response and the vaccine failed to confer tumor rejection in EBI3-deficient mice. Taken together, these results suggest that Ebi3 −/− mice show a phenotype of IL-27-deficiency rather than IL-35-deficiency during anti-tumor T-cell responses. Thus, our results suggest that endogenous IL-27 is critical for both spontaneous and vaccine-induced antitumor T-cell responses.",
keywords = "Epstein-Barr virus-induced gene 3, IL-27, IL-35, Treg, Tumor immunity",
author = "Zhenzhen Liu and Liu, {Jin Qing} and Yun Shi and Xiaotong Zhu and Zhihao Liu and Li, {Ming Song} and Jianhua Yu and Wu, {Lai Chu} and Yukai He and Guoqiang Zhang and Bai, {Xue Feng}",
year = "2015",
month = "1",
day = "1",
doi = "10.4161/2162402X.2014.989137",
language = "English (US)",
volume = "4",
pages = "1--10",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "7",

}

TY - JOUR

T1 - Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth

AU - Liu, Zhenzhen

AU - Liu, Jin Qing

AU - Shi, Yun

AU - Zhu, Xiaotong

AU - Liu, Zhihao

AU - Li, Ming Song

AU - Yu, Jianhua

AU - Wu, Lai Chu

AU - He, Yukai

AU - Zhang, Guoqiang

AU - Bai, Xue Feng

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Epstein-Barr virus-induced gene 3 (EBI3) encoded protein can form heterodimers with IL-27P28, and IL-12P35 to form IL-27, and IL-35. However, IL-27 stimulates, whereas IL-35 inhibits antitumor T-cell responses. IL-27 also limits the Foxp3 + regulatory T cell (Treg) population, whereas IL-35 has been shown to expand Tregs and foster Treg suppressive functions. It remains unclear which group of forces are dominant during antitumor T-cell responses. In this study, we evaluated the tumor growth and antitumor T-cell responses in EBI3-deficient mice that lack both IL-27 and IL-35. We found that injecting B16 melanoma cells into EBI3-deficient C57BL/6 mice, or J558 plasmacytoma cells into EBI3-deficient BALB/c mice resulted in significantly increased tumor growth relative to those implanted in wild-type control mice. Tumors from EBI3-deficient mice contained significantly decreased proportions of CD8 + T cells and increased proportions of CD4 + FoxP3 + Treg cells as compared to those from EBI3-intact mice. Tumor-infiltrating T cells from EBI3-deficient mice were impaired in their capacity to produce IFNγ. Phenotypically, Tregs from EBI3-deficient mice were highly suppressive and produced IL-10 in the tumor microenvironment. Depletion of Tregs or inactivation of the IL-10 pathway significantly abrogated tumor growth enhancement in Ebi3 −/− mice. Finally, we showed that Ebi3 −/− mice administered a melanoma vaccine failed to mount a CD8 + T-cell response and the vaccine failed to confer tumor rejection in EBI3-deficient mice. Taken together, these results suggest that Ebi3 −/− mice show a phenotype of IL-27-deficiency rather than IL-35-deficiency during anti-tumor T-cell responses. Thus, our results suggest that endogenous IL-27 is critical for both spontaneous and vaccine-induced antitumor T-cell responses.

AB - Epstein-Barr virus-induced gene 3 (EBI3) encoded protein can form heterodimers with IL-27P28, and IL-12P35 to form IL-27, and IL-35. However, IL-27 stimulates, whereas IL-35 inhibits antitumor T-cell responses. IL-27 also limits the Foxp3 + regulatory T cell (Treg) population, whereas IL-35 has been shown to expand Tregs and foster Treg suppressive functions. It remains unclear which group of forces are dominant during antitumor T-cell responses. In this study, we evaluated the tumor growth and antitumor T-cell responses in EBI3-deficient mice that lack both IL-27 and IL-35. We found that injecting B16 melanoma cells into EBI3-deficient C57BL/6 mice, or J558 plasmacytoma cells into EBI3-deficient BALB/c mice resulted in significantly increased tumor growth relative to those implanted in wild-type control mice. Tumors from EBI3-deficient mice contained significantly decreased proportions of CD8 + T cells and increased proportions of CD4 + FoxP3 + Treg cells as compared to those from EBI3-intact mice. Tumor-infiltrating T cells from EBI3-deficient mice were impaired in their capacity to produce IFNγ. Phenotypically, Tregs from EBI3-deficient mice were highly suppressive and produced IL-10 in the tumor microenvironment. Depletion of Tregs or inactivation of the IL-10 pathway significantly abrogated tumor growth enhancement in Ebi3 −/− mice. Finally, we showed that Ebi3 −/− mice administered a melanoma vaccine failed to mount a CD8 + T-cell response and the vaccine failed to confer tumor rejection in EBI3-deficient mice. Taken together, these results suggest that Ebi3 −/− mice show a phenotype of IL-27-deficiency rather than IL-35-deficiency during anti-tumor T-cell responses. Thus, our results suggest that endogenous IL-27 is critical for both spontaneous and vaccine-induced antitumor T-cell responses.

KW - Epstein-Barr virus-induced gene 3

KW - IL-27

KW - IL-35

KW - Treg

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=84944458414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944458414&partnerID=8YFLogxK

U2 - 10.4161/2162402X.2014.989137

DO - 10.4161/2162402X.2014.989137

M3 - Article

AN - SCOPUS:84944458414

VL - 4

SP - 1

EP - 10

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 7

ER -